According to the research report, the global diabetes drug market size is expected to touch USD 118 Billion by 2032, from USD 61.87 Billion in 2022, growing with a significant CAGR of 6.67% from 2023 to 2032.
The diabetes drug report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global diabetes drug in conjunction with the geographical landscape of this vertical have also been included in this report.
The report offers intricate dynamics about different aspects of the global diabetes drug market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global diabetes drug during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).
Sample Link @ https://www.precedenceresearch.com/sample/2886
Report Scope of the Diabetes Drug Market:
| Report Coverage | Details |
| Market Size in 2023 | USD 66 Billion |
| Market Size by 2032 | USD 118 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 6.67% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Drug class, BY Diabetes Type, and By Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
This study covers a detailed segmentation of the global diabetes drug market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global diabetes drug market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.
Key Players
- Novo Nordisk A/s
- Sanofi
- Merck & Co, Inc
- Eli Lilly and Company
- AstraZeneca
- Takeda Pharmaceuticals Company Limited
- Boehringer Ingelheim International GmbH
- Novartis AG
- Johnson & Johnson Services, Inc.
- Bayers AG
Market Segmentation
By Drug Class
- Insulin
- DPP- 4 Inhibitors
- GLP-1 Receptor Agonists
- SGLT2 Inhibitors
By Diabetes Type
- Type 1
- Type 2
By Route of Administration
- Oral
- Subcutaneous
- Intravenous
By Distribution Channel
- Online pharmacies
- Hospital Pharmacies
- Retail pharmacies
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Research Methodology
The research methodology adopted by analysts for compiling the global diabetes drug report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global diabetes drug market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Diabetes Drug Market
5.1. COVID-19 Landscape: Diabetes Drug Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Diabetes Drug Market, By Drug Class
8.1. Diabetes Drug Market Revenue and Volume Forecast, by Drug Class, 2023-2032
8.1.1. Insulin
8.1.1.1. Market Revenue and Volume Forecast (2020-2032)
8.1.2. DPP- 4 Inhibitors
8.1.2.1. Market Revenue and Volume Forecast (2020-2032)
8.1.3. GLP-1 Receptor Agonists
8.1.3.1. Market Revenue and Volume Forecast (2020-2032)
8.1.4. SGLT2 Inhibitors
8.1.4.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 9. Global Diabetes Drug Market, By Diabetes Type
9.1. Diabetes Drug Market Revenue and Volume Forecast, by Diabetes Type, 2023-2032
9.1.1. Type 1
9.1.1.1. Market Revenue and Volume Forecast (2020-2032)
9.1.2. Type 2
9.1.2.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 10. Global Diabetes Drug Market, By Route of Administration
10.1. Diabetes Drug Market Revenue and Volume Forecast, by Route of Administration, 2023-2032
10.1.1. Oral
10.1.1.1. Market Revenue and Volume Forecast (2020-2032)
10.1.2. Subcutaneous
10.1.2.1. Market Revenue and Volume Forecast (2020-2032)
10.1.3. Intravenous
10.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 11. Global Diabetes Drug Market, By Distribution Channel
11.1. Diabetes Drug Market Revenue and Volume Forecast, by Distribution Channel, 2023-2032
11.1.1. Online pharmacies
11.1.1.1. Market Revenue and Volume Forecast (2020-2032)
11.1.2. Hospital Pharmacies
11.1.2.1. Market Revenue and Volume Forecast (2020-2032)
11.1.3. Retail pharmacies
11.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 12. Global Diabetes Drug Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
12.1.2. Market Revenue and Volume Forecast, by Diabetes Type (2020-2032)
12.1.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.1.4. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
12.1.5.2. Market Revenue and Volume Forecast, by Diabetes Type (2020-2032)
12.1.5.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.1.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
12.1.6.2. Market Revenue and Volume Forecast, by Diabetes Type (2020-2032)
12.1.6.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
12.2.2. Market Revenue and Volume Forecast, by Diabetes Type (2020-2032)
12.2.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.2.4. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
12.2.5.2. Market Revenue and Volume Forecast, by Diabetes Type (2020-2032)
12.2.5.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.2.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
12.2.6.2. Market Revenue and Volume Forecast, by Diabetes Type (2020-2032)
12.2.6.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.2.6.4. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
12.2.7.2. Market Revenue and Volume Forecast, by Diabetes Type (2020-2032)
12.2.7.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.2.7.4. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
12.2.8.2. Market Revenue and Volume Forecast, by Diabetes Type (2020-2032)
12.2.8.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.2.8.4. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
12.3.2. Market Revenue and Volume Forecast, by Diabetes Type (2020-2032)
12.3.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.3.4. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
12.3.5.2. Market Revenue and Volume Forecast, by Diabetes Type (2020-2032)
12.3.5.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.3.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
12.3.6.2. Market Revenue and Volume Forecast, by Diabetes Type (2020-2032)
12.3.6.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
12.3.7.2. Market Revenue and Volume Forecast, by Diabetes Type (2020-2032)
12.3.7.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.3.7.4. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
12.3.8.2. Market Revenue and Volume Forecast, by Diabetes Type (2020-2032)
12.3.8.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
12.4.2. Market Revenue and Volume Forecast, by Diabetes Type (2020-2032)
12.4.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.4.4. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
12.4.5.2. Market Revenue and Volume Forecast, by Diabetes Type (2020-2032)
12.4.5.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.4.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
12.4.6.2. Market Revenue and Volume Forecast, by Diabetes Type (2020-2032)
12.4.6.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
12.4.7.2. Market Revenue and Volume Forecast, by Diabetes Type (2020-2032)
12.4.7.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.4.7.4. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
12.4.8.2. Market Revenue and Volume Forecast, by Diabetes Type (2020-2032)
12.4.8.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
12.5.2. Market Revenue and Volume Forecast, by Diabetes Type (2020-2032)
12.5.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
12.5.5.2. Market Revenue and Volume Forecast, by Diabetes Type (2020-2032)
12.5.5.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.5.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)
12.5.6.2. Market Revenue and Volume Forecast, by Diabetes Type (2020-2032)
12.5.6.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
Chapter 13. Company Profiles
13.1. Novo Nordisk A/s
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Bayers AG
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Sanofi
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Merck & Co, Inc
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Eli Lilly and Company
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. AstraZeneca
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Takeda Pharmaceuticals Company Limited
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Boehringer Ingelheim International GmbH
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Novartis AG
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Johnson & Johnson Services, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments